Evinacumab in Patients with Refractory Hypercholesterolemia

Area of Science:

• Cardiology
• Pharmacology
• Genetics

Background:

• Patients with refractory hypercholesterolemia have elevated low-density lipoprotein (LDL) cholesterol despite maximal lipid-lowering therapies, increasing atherosclerosis risk.
• The efficacy and safety of evinacumab, a monoclonal antibody targeting angiopoietin-like 3, were previously unknown in this patient population.

Purpose of the Study:

• To evaluate the efficacy and safety of subcutaneous and intravenous evinacumab in patients with refractory hypercholesterolemia.
• To determine the impact of evinacumab on LDL cholesterol levels compared to placebo.

Main Methods:

• A double-blind, placebo-controlled, phase 2 trial enrolled patients with refractory hypercholesterolemia.
• Participants received varying doses of subcutaneous or intravenous evinacumab or placebo.
• The primary endpoint was the percent change in LDL cholesterol from baseline at week 16.

Main Results:

• Subcutaneous evinacumab (450 mg weekly) reduced LDL cholesterol by 56.0% compared to placebo (P<0.001).
• Intravenous evinacumab (15 mg/kg every 4 weeks) reduced LDL cholesterol by 50.5% compared to placebo (P<0.001).
• Serious adverse event incidence ranged from 3-16% across groups.

Conclusions:

• Evinacumab significantly reduced LDL cholesterol levels in patients with refractory hypercholesterolemia.
• The maximum dose of evinacumab achieved over a 50% reduction in LDL cholesterol.
• Evinacumab shows promise as a treatment for refractory hypercholesterolemia.